Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HESC- and hiPSC-derived Schwann cells are Molecularly and Functionally Equivalent

ABSTRACT: hESC- and hiPSC-derived Schwann cells are Molecularly and Functionally Equivalent

PROVIDER: PRJNA860642 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR20336600_1.fastq.gz	Fastqsanger.gz
	SRR20336600_2.fastq.gz	Fastqsanger.gz
	SRR20336595_1.fastq.gz	Fastqsanger.gz
	SRR20336595_2.fastq.gz	Fastqsanger.gz
	SRR20336596_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

hESC- and hiPSC-derived Schwann cells are Molecularly and Functionally Equivalent

Project description:Establishing robust models of human myelinating Schwann cells is critical for studying peripheral nerve injury and disease. Stem cell differentiation has emerged as a key model of human cells and disease motivating development of Schwann cell differentiation protocols. Human embryonic stem cells (hESCs) are considered the ideal pluripotent cell but ethical concerns regarding their use have propelled the popularity of human induced pluripotent stem cells (hiPSCs). Given that the equivalence of hESCs and hiPSCs remains controversial, we sought to compare the molecular and functional equivalence of hESC- and hiPSC-derived Schwann cells generated with our previously reported protocol. We identified only modest transcriptome differences by RNA sequencing and insignificant proteome differences by antibody array. Additionally, both cell types comparably improved nerve regeneration and function in a chronic denervation and regeneration animal model. Our findings demonstrate that Schwann cells derived from hESCs and hiPSCs with our protocol are molecularly comparable and functionally equivalent.

2024-05-29 | GSE208708 | GEO

Development of cell therapy against CKD using functionally enhanced hiPSC-derived nephron progenitor cells(hiPSC-NPCs)

Project description:we identified the differentially expressed genes (DEGs) in hiPSC-NPCs exposed to conditioned media from hiPSC-NPCs transfected with hepatocyte growth factor (HGF-NPCs) by transcriptome analysis.

2025-04-01 | GSE228035 | GEO

Development of cell therapy against CKD using functionally enhanced hiPSC-derived nephron progenitor cells (hiPSC-NPCs)

2025-04-01 | GSE228209 | GEO

Generation of phenotypically stable and functionally mature human bone marrow MSCs derived Schwann cells via the induction of human iPSCs-derived sensory neurons

Project description:Phenotypically unstable Schwann cell-like cells (SCLCs), derived from mesenchymal stem cells (MSCs) require intercellular contact-mediated cues for Schwann cell (SCs)-fate commitment. Although rat dorsal root ganglion (DRG) neurons provide contact-mediated signals for the conversion of SCLCs into fate-committed SCs, the use of animal cells is clinically unacceptable. To overcome this problem, we previously acquired human induced pluripotent stem cell-derived sensory neurons (hiPSC-dSNs) as surrogates of rat DRG neurons that committed rat bone marrow SCLC to the SC fate. Therefore, in this study, we explored whether hiPSC-dSNs could mimic rat DRG neurons effects to obtain fate-committed SCs from hBMSC-derived SCLC. The derived cells exhibited bi-/tri-polar morphology of SCs and maintained the expression of the SC markers S100, p75NTR, p0, GFAP, and Sox10, even after withdrawing the glia-inducing factors or hiPSC-dSNs cues. Electronic microscopy and RNA-seq analysis further provided evidence that human BMSC-dSCs were similar to the original human SCs in terms of their function and a variety of characteristics. Furthermore, these cells formed myelin basic protein-positive segments and secreted neurotrophic factors to facilitate the neurite outgrowth of Neuro2A, demonstrating that they were functionally mature. Our results provide a promising approach through which stable and fully developed hBMSC-dSCs can be used for transplantation and myelin sheath regeneration following traumatic nerve injuries.

2025-03-05 | GSE271519 | GEO

Modeling CMT1A with human induced pluripotent stem cell derived Schwann cells

Project description:We obtained skin fibroblasts from CMT1A and control patients, and generated hiPSCs which were subsequently differentiated into cd49d+ human Schwann cells. We utilized microarray technology to explore the gene expression profiles of cd49d+ Schwann cells CMT1A hiPSCs, control hiPSCs, and control human embryonic stem cells in order to identify potentially disregulated pathways contributing to CMT1A pathogenesis. Patient-specific human induced pluripotent stem cells (hiPSCs) hold great promise for disease modeling of genetic disorders. Often the findings from hiPSC-based studies are validated with genetically-corrected hiPSCs generated by precise genome editing technologies, however, alternatives that have not yet been employed are validation with embryonic stem cells harboring the same disease mutation or utilizing another reprogramming approach from somatic cells of same patients. Here we report that disease-relevant phenotypes found in Charcot-Marie-Tooth 1A (CMT1A)-hiPSC-derived Schwann cells were further confirmed by two additional congruent CMT1A models as an alternative to gene correction. We have devised a defined and relatively fast protocol for the direct derivation and prospective isolation of Schwann cells from hiPSCs, leading us to uncover a phenotype of dysregulated immune signaling in CMT1A-hiPSCs-Schwann cells. Our study illustrates the promise of applying hiPSC technology to one of the most common hereditary neuropathies for gaining new insights into human disease pathogenesis and treatment, and these results demonstrate the feasibility of verifying disease phenotypes by utilizing the malleability of cellular fates.

2019-05-22 | GSE69988 | GEO

Three congruent human Schwann cell models of CMT1A reveal a converged phenotype

Project description:Three CMT1A patient Schwann cell populations which were derived from hESC, hiPSC, or direct converted hiNC share the disease relevant phenotypes. From comparing deep sequencing results of these populations, potential therapeutic targets were newly identified.

2019-08-15 | GSE85598 | GEO

Schwann cell condition medium MS

Project description:The effects of Schwann cells on the neuro-stroma niche in pancreatic ductal adenocarcinoma (PDAC) remain to be explored. Here, single-cell RNA-sequencing and spatial transcriptome analysis of PDAC tissues reveals that Schwann cells induce malignant subtypes of tumour cells and cancer-associated fibroblasts. Mass Spectrometry (MS) were performed to detected the potential functional factors secreted by Schwann cells.

2023-06-27 | PXD042556 | Pride

Molecularly defined and functionally distinct subcircuits of the medial mammillary nucleus

Project description:Molecularly defined and functionally distinct subcircuits of the medial mammillary nucleus

| PRJNA1046024 | ENA

Schwann Cell Tn5Prime

Project description:Schwann Cell Tn5Prime

| PRJNA579292 | ENA

Development of cell therapy against CKD using functionally enhanced hiPSC-derived nephron progenitor cells(hiPSC-NPCs)

Project description:Development of cell therapy against CKD using functionally enhanced hiPSC-derived nephron progenitor cells(hiPSC-NPCs)

| PRJNA947909 | ENA